Skip Nav Destination
1-10 of 10
Acta Haematol 1–3.
Published Online: 07 August 2023
...Stefano Molica; Marco Rossi; David Allsup In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus...
M. Teresa Cibeira, José T. Ortiz-Pérez, Luis F. Quintana, Carlos Fernádez de Larrea, Natalia Tovar, Joan Bladé
Acta Haematol (2020) 143 (4): 335–342.
Published Online: 01 April 2020
... treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response. The decrease in the production of the amyloidogenic light chains is a required condition to obtain the organ response, which is commonly delayed. Meanwhile, supportive...
Xiao-Fan Zhu, Hai-Long He, Shun-Qing Wang, Jing-Yan Tang, Bing Han, Dong-Hua Zhang, Li-Qiang Wu, De-Pei Wu, Wei Li, Ling-Hui Xia, Huan-Ling Zhu, Feng Liu, Hong-Xia Shi, Xi Zhang, Fang Zhou, Jian-Da Hu, Jian-Pei Fang, Xie-Qun Chen, Tie-Zhen Ye, Ying-Min Liang, Jie Jin, Feng-Kui Zhang
Acta Haematol (2019) 142 (3): 162–170.
Published Online: 15 May 2019
... transplantation (HSCT) or immunosuppressive therapy (IST) comprising antithymocyte globulin (ATG) with cyclosporine (CsA) as initial treatment for AA patients. With limited epidemiological data on the clinical management of AA in Asia, a prospective cohort registry study involving 22 AA treatment centers in China...
Acta Haematol (2016) 135 (3): 172–190.
Published Online: 01 March 2016
..., a pursuit for organ involvement is essential, with a focus on heart involvement, even in the absence of suggestive symptoms for involvement, as this has both prognostic and treatment implications. Details regarding initial treatment options, including stem cell transplantation, are provided in this review...
Acta Haematol (2014) 132 (3-4): 274–278.
Published Online: 10 September 2014
...Ron D. Jachimowicz; Andreas Engert Cancer in the adolescent and young adult (AYA) is the second leading cause of nonaccidental death with hematological malignancies spiking during this period. Treatment of AYAs with hematological malignancies usually follows either pediatric or adult protocols...
Acta Haematol (1987) 78 (Suppl. 1): 157–162.
Published Online: 25 February 2009
... to in the content or advertisements. Complete remission Non-Hodgkin’s lymphomas Treatment Hemato-Oncology and Hemato-Immunology. Proc. 2nd Int. Conf., Catania 1986 Acta haemat. 78: suppl. l,pp. 157-162(1987...
Acta Haematol (2005) 114 (1): 52–60.
Published Online: 01 July 2005
...A. Tefferi The recent discovery of an eosinophilia-specific, imatinib-sensitive, karyotypically occult but fluorescence in situ hybridization-apparent molecular lesion in a subset of patients with blood eosinophilia has transformed the diagnostic as well as treatment approach to eosinophilic...
Samo Zver, Nadja Kokalj Vokac, Boris Zagradisnik, Alenka Erjavec, Andreja Zagorac, Irena Preloznik Zupan, Peter Cernelc
Acta Haematol (2004) 111 (3): 168–170.
Published Online: 26 March 2004
... Organization for Research and Treatment of Cancer. Semin Oncol 2000;27(suppl 5):52–57. 6. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D: The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12...
J. Jaime Caro, Alexandra Ward, Traci Craig Green, Krista Huybrechts, Alejandro Arana, Suzanne Wait, Androulla Eleftheriou
Acta Haematol (2002) 107 (3): 150–157.
Published Online: 25 April 2002
...J. Jaime Caro; Alexandra Ward; Traci Craig Green; Krista Huybrechts; Alejandro Arana; Suzanne Wait; Androulla Eleftheriou Objective: To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs...
Acta Haematol (1998) 99 (2): 57–64.
Published Online: 19 March 1998
... and tumor bulk used to identify high-risk patients with non-Hodgkin’s lymphomas, do not appear to correlate with disease activity or prognosis in AILD. Treatment of AILD has been unsatisfactory, with approximately 25% of patients achieving complete and sustained remission when combined chemotherapy agents...